NCT05618301 - Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 7, 2023

Primary Completion Date

June 24, 2025

Study Completion Date

June 24, 2025

Conditions

Sickle Cell Disease

Interventions

DRUG

Motixafortide

Motixafortide is to be administered as a subcutaneous injection at a dose of 1.25 mg/kg

DRUG

Natalizumab

Natalizumab will be administered as an IV infusion at a flat dose of 300 mg

PROCEDURE

Leukapheresis

Leukapheresis consisting of a 1 Blood Volume procedure

Trial Locations (1)

Washington University School of Medicine, St Louis